Safe. Simple. Certain.

Accurate and rapid testing, right in the allergist’s office

Results in minutes

Less invasive

Accurate

More convenient

Accurate allergy blood test results in a single visit

Kenota revolutionizes allergy testing with lab-quality IgE testing capability in the allergists’ offices, giving them additional information they can use to quickly and accurately diagnose allergies in a single visit.

Allergy testing is crucial

In the U.S. 32 million people suffer from food allergies. Many are life threatening and testing is crucial.

LEARN MORE ABOUT ALLERGY TESTING

Kenota Health is transforming the allergy testing experience for patients by giving allergists a better, faster way to obtain highly specific test results right in the allergist's office.

Assess allergies in minutes

Kenota is decentralizing allergy testing with a proprietary approach that employs rapid, point of care instrumentation. Capable of swiftly quantifying a patient’s sensitization to allergens, our system is compact, streamlined and can be administered easily by allergists and their staff.

Designed with allergists in mind

Uncovers sensitizations with a few drops of blood

Easy to administer: results and reports generated on the spot

Allergists can provide end-to-end care in a single visit – no need for lab referrals

Milestones

Developed concept for in-clinic allergy testing system

Established scalable 33,000 square-foot manufacturing facility in Waterloo Region, Canada

Raised $11 million in Series A funding

Clinical studies completed

510(k) clearance and CLIA waiver approval

Kenota in the news

Kenota Health Announces FDA 510(k) with CLIA Waiver Approval


JUNE 2024


Kenota has received the first-ever CLIA Wavier Approval for in office testing of Total IgE for Allergists and Immunologists. The Kenota 1 system delivers test results in less than 30 minutes with just a fingerstick sample of blood.
Click here to read more.

Read more

Kenota Health Announces FDA Submission for Allergy System


JULY 2023


Kenota Health is pleased to announce that the FDA has accepted a Dual Track (Dual 510(k) and CLIA Waiver by Application) submission for their new device, the Kenota 1 System and Kenota 1 Total IgE assay. The system, with its first assay (total IgE), has been designed to bring quantitative IgE testing to the allergy clinic without the need for a full CLIA laboratory license.
Click here to read more.

Read more

Kenota Health strengthens Board of Directors


MARCH 2022


Kenota has added US diagnostic business leaders Ruth Abdulmassih and Dennis Flannelly to its board of directors. Both bring extensive experience that will help guide Kenota as it advances toward complete development and clearance of its product. “The addition of Dennis and Ruth to the Kenota board is a significant step forward for our company,” stated Kenota CEO and Founder, Moufeed Kaddoura.
Click here to read more.

Read more

Kenota to present at 2021 Venture Summit


JANUARY 2021


In this virtual summit, Moufeed Kaddoura, founder and CEO of Kenota will join other leading early stage and emerging growth innovators as they present live to top investors.

Read more

Moufeed Kaddoura to present at Life Science Intelligence Summit


JANUARY 2021


Kenota’s founder and CEO to present at the 2021 Emerging Medtech Summit, which brings together “the most innovative medtech startups, active investors and strategic buyers to deal-make and collaborate about the future of our industry.”

Read more

Kenota Health raises $11M in funding


DECEMBER 2020


Kenota has raised $11 million in funding to provide rapid, reliable, point of care allergy testing. An initial seed round of $2 million in 2016 was used to begin validating our approach with physicians, followed by a Series A of $9 million, led by leading global venture fund, Draper Associates — the first institutional investor to back Tesla, Benchling, Robinhood, Skype, Hotmail and more than 20 other unicorns.
Click here for article.

Read more